Chargement en cours...
HDAC1, a novel marker for benign teratomas
Histone deacetylases (HDACs) are attractive chemotherapy targets, owing to their pro-proliferative activities. However, the finding that loss of HDAC1 promotes teratoma malignancy calls for caution in the use of HDAC inhibitors as cancer therapeutics.
Enregistré dans:
| Auteurs principaux: | , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Nature Publishing Group
2010
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3020642/ https://ncbi.nlm.nih.gov/pubmed/21124297 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/emboj.2010.281 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|